Department of Medicine, Division of Nephrology, Jacobs School of Medicine and Biomedical Sciences, and.
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
JCI Insight. 2021 Jun 8;6(11):144410. doi: 10.1172/jci.insight.144410.
Patients with chronic kidney disease (CKD) and end-stage renal disease suffer from increased cardiovascular events and cardiac mortality. Prior studies have demonstrated that a portion of this enhanced risk can be attributed to the accumulation of microbiota-derived toxic metabolites, with most studies focusing on the sulfonated form of p-cresol (PCS). However, unconjugated p-cresol (uPC) itself was never assessed due to rapid and extensive first-pass metabolism that results in negligible serum concentrations of uPC. These reports thus failed to consider the host exposure to uPC prior to hepatic metabolism. In the current study, not only did we measure the effect of altering the intestinal microbiota on lipid accumulation in coronary arteries, but we also examined macrophage lipid uptake and handling pathways in response to uPC. We found that atherosclerosis-prone mice fed a high-fat diet exhibited significantly higher coronary artery lipid deposits upon receiving fecal material from CKD mice. Furthermore, treatment with uPC increased total cholesterol, triglycerides, and hepatic and aortic fatty deposits in non-CKD mice. Studies employing an in vitro macrophage model demonstrated that uPC exposure increased apoptosis whereas PCS did not. Additionally, uPC exhibited higher potency than PCS to stimulate LDL uptake and only uPC induced endocytosis- and pinocytosis-related genes. Pharmacological inhibition of varying cholesterol influx and efflux systems indicated that uPC increased macrophage LDL uptake by activating macropinocytosis. Overall, these findings indicate that uPC itself had a distinct effect on macrophage biology that might have contributed to increased cardiovascular risk in patients with CKD.
患有慢性肾脏病 (CKD) 和终末期肾病的患者会遭受心血管事件和心脏死亡率增加的困扰。先前的研究表明,这种风险增加的一部分可以归因于微生物群衍生的有毒代谢物的积累,大多数研究都集中在对甲酚的磺化形式(PCS)上。然而,由于快速且广泛的首过代谢,未对未结合的对甲酚(uPC)本身进行评估,这导致 uPC 的血清浓度可忽略不计。这些报告因此未能考虑到 uPC 在肝脏代谢之前宿主对其的暴露。在本研究中,我们不仅测量了改变肠道微生物群对冠状动脉脂质积累的影响,还研究了巨噬细胞脂质摄取和处理途径对 uPC 的反应。我们发现,喂食高脂肪饮食的易患动脉粥样硬化的小鼠在接受 CKD 小鼠的粪便物质后,冠状动脉脂质沉积明显增加。此外,uPC 治疗在非 CKD 小鼠中增加了总胆固醇、甘油三酯以及肝和主动脉脂肪沉积。使用体外巨噬细胞模型的研究表明,uPC 暴露会增加细胞凋亡,而 PCS 则不会。此外,uPC 比 PCS 刺激 LDL 摄取的能力更强,只有 uPC 诱导内吞作用和胞饮作用相关基因。不同胆固醇内流和外排系统的药理学抑制表明,uPC 通过激活巨胞饮作用增加了巨噬细胞的 LDL 摄取。总的来说,这些发现表明 uPC 本身对巨噬细胞生物学有明显的影响,这可能导致 CKD 患者心血管风险增加。